Exciting Leadership Changes at Jeune Aesthetics
PITTSBURGH – Jeune Aesthetics, Inc. is thrilled to announce the appointment of Marc Forth as their new Chief Executive Officer (CEO). Jeune, a key subsidiary of Krystal Biotech, Inc. (NASDAQ: KRYS), is committed to transforming the landscape of skincare by using advanced gene delivery technology aimed at countering the effects of aging on the skin.
Marc Forth: A Seasoned Executive
Marc Forth, a dynamic figure in the healthcare sector, brings over 30 years of extensive experience in commercial and executive leadership roles. His impressive career includes significant contributions to renowned brands like BOTOX, propelling its status as one of the world's leading aesthetics brands. Since February 2021, Forth has also played a pivotal role on Jeune’s board of directors, providing strategic insights and guidance.
Vision for the Future
Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics, expresses his enthusiasm for Forth’s appointment, stating, “Marc’s rich history in leadership will greatly help us as we aim for the next level of growth at Jeune.” The shared goal is to harness Krystal’s innovative gene delivery platform to enhance the effectiveness and availability of rejuvenative aesthetics treatments.
Transforming Aesthetic Treatments
Prior to taking on the CEO role at Jeune, Mr. Forth served as President and CEO of AEON Biopharma. He led efforts around the therapeutic application of a botulinum toxin, ABP-450, guiding its clinical development across various medical fields. Before AEON, Forth worked at Allergan PLC, where he oversaw U.S. divisions including Neurosciences and Medical Dermatology, contributing immensely to product commercialization.
Commitment to Innovation
As a proactive leader, Forth is eager to capitalize on Jeune’s unique position in the aesthetics market. “Joining Jeune marks an exciting milestone in my career,” he reflects. “With Krystal’s FDA-validated gene delivery system as our foundation, we look forward to addressing the rising need for effective rejuvenative solutions for aging skin.”
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc. is dedicated to harnessing cutting-edge biotechnology to reverse the aging process in skin. As part of Krystal Biotech, Jeune leverages a validated gene delivery platform designed to tackle the complexities of age-related skin changes. This innovative approach signifies a new era in aesthetic treatments, enhancing the quality of patient care.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pioneering biotechnology company focusing on genetic medicines to treat significant unmet medical needs. Its flagship product, VYJUVEK, is the first redosable gene therapy approved by the FDA for dystrophic epidermolysis bullosa. Krystal Biotech is rapidly expanding its diverse pipeline of genetic therapies across various therapeutic areas, including dermatology and aesthetics.
Frequently Asked Questions
What is the main focus of Jeune Aesthetics?
Jeune Aesthetics focuses on innovative gene delivery technology to address and reverse the effects of aging on the skin.
Who is the newly appointed CEO of Jeune Aesthetics?
Marc Forth has been appointed as the new CEO of Jeune Aesthetics, bringing extensive experience in the healthcare sector.
What is Marc Forth's background?
Marc Forth has over 30 years of leadership experience in the healthcare industry, including significant roles at allergan and AEON Biopharma.
How does Jeune Aesthetics enhance skin rejuvenation?
Jeune Aesthetics utilizes a clinically validated gene delivery platform to provide fundamentally rejuvenative treatments for aging skin.
What is the relationship between Jeune Aesthetics and Krystal Biotech?
Jeune Aesthetics is a wholly owned subsidiary of Krystal Biotech, which provides the innovative gene delivery technology that Jeune uses.
